CJC-1295 w/ DAC 5mg
$ 65.00
CJC-1295 w/ DAC is a synthetic 29–amino acid analog of growth hormone–releasing hormone (GHRH) designed to increase endogenous growth hormone (GH) production. The peptide includes four amino acid substitutions to improve stability and pharmacokinetics. Its DAC (Drug Affinity Complex) component extends the half-life to approximately 6–8 days by enabling plasma protein binding, while maintaining receptor affinity.
All peptides offered by 1stPharma are produced through the lyophilization (freeze-drying) process, a method that preserves molecular stability during handling and transport for approximately 3–4 months. Once reconstituted with bacteriostatic water, the solution must be stored under refrigeration to maintain integrity, where it generally remains viable for up to 30 days. Lyophilization, also referred to as cryodesiccation, is a specialized dehydration technique in which the compound is frozen and then placed under reduced pressure. This causes the frozen water content to sublimate directly from solid ice to vapor, leaving behind a stable, crystalline peptide powder. The resulting white, porous material can be kept at room temperature until reconstitution is required. After delivery, peptides should be safeguarded from light exposure and stored in a cool environment. For short-term use spanning several days to weeks, refrigeration at or below 4°C (39°F) is recommended. While lyophilized peptides may remain structurally intact at room temperature for weeks, cold storage provides added assurance of stability for ongoing research. For extended preservation lasting months or years, ultra-low freezing is preferred. Storage at –80°C (–112°F) offers the most reliable option for maintaining peptide quality and consistency over long durations. For detailed guidance on peptide handling and storage protocols, please refer to: Peptide Storage Information – 1stPharma.com For extended preservation, particularly for storage spanning multiple months to years, peptides are best kept in ultra-low freezers at approximately –80°C (–112°F). Under these long-term conditions, structural stability is maximized, ensuring peptides retain their quality and suitability for future research applications.
Overview
Mechanism: CJC-1295 DAC acts as a GHRH analog, stimulating GH release from somatotroph cells. Study Insights: It has been studied for effects on fat metabolism, lean mass preservation, bone health, and sleep regulation through GH pathways. Key Findings: Its long-acting profile and GH-releasing activity make it a focus of research in metabolic and regenerative contexts.
Chemical Makeup
Molecular Formula: C152H252N44O42
Molecular Weight: 3367.95 g/mol
Other Names: CJC-1295, CJC-1295 with DAC, DAC: GRF, Long-acting GHRH analog
Mechanism of Action
Mechanism: CJC-1295 DAC binds to GHRH receptors on somatotroph cells, activating G-protein–mediated signaling and secondary messengers like cAMP. This leads to phosphorylation of transcription regulators and enhanced GH gene expression. GH then stimulates IGF-1 production in the liver and other tissues via the JAK-STAT pathway. Key Findings: The peptide prolongs GH stimulation while maintaining receptor activity, enabling sustained IGF-1 elevation.
GH Pulsatility & IGF-1 Studies
Mechanism: CJC-1295 DAC boosts GH pulsatility and elevates circulating IGF-1 through sustained stimulation of somatotroph cells. Study Insights: Clinical studies reported clear increases in GH secretion and IGF-1 levels after both single and repeated administrations. Key Findings: Repeated exposure produces prolonged GH and IGF-1 elevation well beyond typical GHRH analog durations.
Animal Studies & Body Composition
Mechanism: In animal models, CJC-1295 DAC stimulates GH production even in GHRH-deficient states. Study Insights: Regular administration preserved lean mass and reduced fat accumulation compared to controls. Key Findings: Research suggests potential impacts on muscle and bone structure while maintaining normal fat levels.
Half-life & Structural Modifications
Mechanism: Four amino acid substitutions at positions 2, 8, 15, and 27 increase enzymatic resistance, while DAC technology extends plasma half-life. Study Insights: These modifications improve bioavailability and peptide stability against degradation. Key Findings: The result is a long-acting GHRH analog with a half-life extended from minutes to several days.
Ancillary Studies
Mechanism: CJC-1295 DAC has been explored for various applications including visceral obesity in HIV models. Study Insights: Some studies were discontinued or exploratory, but regulatory testing has confirmed its classification as a GH-releasing factor. Key Findings: It remains under investigation for diverse metabolic and endocrine research contexts.
Disclaimer
All products offered by 1stPharma.com are intended strictly for laboratory and scientific research purposes only. These products are not approved by the FDA, are not medicines or supplements, and are not sold for human consumption, medical treatment, or veterinary use. Any discussion of potential benefits is based solely on preclinical findings.
| Packing |
5mg |
|---|
Reviews
There are no reviews yet.